Efficacy and safety of TAF prophylactic administration for HBV reactivation hepatitis during immunosuppressive or anti-tumor therap
Not Applicable
Recruiting
- Conditions
- Patients with current or previous HBV infection
- Registration Number
- JPRN-UMIN000035046
- Lead Sponsor
- Hokkaido university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a past history of hypersensitivity to TAF 2) Patients with serious liver dysfunction (Child-Pugh Class B or C) 3) Patients with difficult-to-control heart disease (e.g., myocardial infarction, heart failure, and arrhythmia) 4) Liver transplantation 5) Patients who are not expected to be survived more than 12 month by the primary physician. 6) Other patients judged to be inappropriate to participate in the study by the primary physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method